The FY21 PCRP Translational Science Award (TSA) mechanism supports advanced translational research that will foster transformation of promising ideas in prostate cancer into clinical applications, ultimately providing a solution to one or more of the FY21 PCRP Overarching Challenges. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside, but can include a reciprocal flow of ideas and information between basic science and clinical science (bench to bedside and/or bedside to bench). This mechanism is intended to fund a broad range of translational studies including, but not limited to, the following:
• Advanced preclinical studies aimed at translating results from animal studies to applications with human samples/cohorts. The TSA is not intended to support initial mechanistic studies of a new target.
• Late-stage preclinical work leading to/preparing for a clinical trial, e.g., an Investigational New Drug (IND) application submission
• Correlative studies that are associated with an open/ongoing or completed clinical trial, e.g., projects that utilize biospecimens from clinical trials to improve clinical management of prostate cancer and/or define new areas of research
• Projects that develop endpoints for clinical trials
• Required Pre-Application Deadline: July 15, 2021
• Application Submission Deadline: July 29, 2021